DiaSorin SpA (34D)

97.500
-2.600(-2.60%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    97.500 - 97.500
Trading near 52-week Low

Diasorin has hit the lowest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

34D Overview

Prev. Close
100.1
Day's Range
97.5-97.5
Revenue
654.64M
Open
97.5
52 wk Range
97.5-147.1
EPS
5.25
Volume
0
Market Cap
5.45B
Dividend (Yield)
1.05
(0.99%)
Average Vol. (3m)
113
P/E Ratio
19.41
Beta
0.246
1-Year Change
-24.65%
Shares Outstanding
53,387,763
Next Earnings Date
May 11, 2023
What is your sentiment on Diasorin?
or
Market is currently closed. Voting is open during market hours.

DiaSorin SpA Company Profile

DiaSorin SpA Company Profile

Employees
3350
Market
Italy
  • Type:Equity
  • Market:Germany
  • ISIN:IT0003492391
  • WKN:A0MTB2

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.

Read More

Analyst Price Target

Average122.733 (+20.268% Upside)
High140.000
Low91.000
Price102.050
No. of Analysts12
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Che successe, mentre il resto sale?
    0
    • superata la curva alta di Bollinger,  punta a 160 ?
      0
    • Tobias Raederwell said! It did it now
      0
  • Overrated company, in my opinion you can sell Short Diasorin capitalization 11 billion euros Profits 175 million euros Turnover 800 million ISIN IT0003492391 diasorin
    7
    • short!!
      7
      • alla faccia del fattoquotidiano che oggi ha provato a dare un'altra spallata a questo gioiello... Coronavirus: da Fda via libera a test sierologico DiaSorin L'autorizzazione per analisi validata al San Matteo di Pavia (ANSA) - ROMA, 25 APR - DiaSorin annuncia di aver ricevuto l'Emergency Use Authorization (EUA) dalla Food and Drug Administration americana per il test LIAISON  SARS-CoV-2 S1/S2 IgG. Si tratta del nuovo test sierologico validato presso il Policlinico San Matteo a Pavia, uno dei centri di riferimento nazionali per la pandemia da COVID-19.
        3
        • DIASORIN COVID fast test has been approved by FDA
          0
          • nice news, not sure why is going down anyway
            0
          • When??????
            0
        • USA: Dow e NASDAQ han chiuso a +10%. Lunedì si parte da 120.10€. Buon weekend
          1
          • E invece... 109.90€ :D
            0
        • DiaSorin’s test could be ready within six weeks for consideration by the U.S. Food and Drug Administration, and the QIAGEN test could be ready within 12 weeks for FDA consideration, according to HHS.
          0
          • They just announced a fast test for COVID-19, 60 minutes against some hours
            0
            • 150€ during this year ?
              1